792 related articles for article (PubMed ID: 34297684)
1. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.
Bartalena L; Kahaly GJ; Baldeschi L; Dayan CM; Eckstein A; Marcocci C; Marinò M; Vaidya B; Wiersinga WM;
Eur J Endocrinol; 2021 Aug; 185(4):G43-G67. PubMed ID: 34297684
[TBL] [Abstract][Full Text] [Related]
2. Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)].
Nowak M; Marek B; Kos-Kudła B; Siemińska L; Londzin-Olesik M; Głogowska-Szeląg J; Nowak W; Kajdaniuk D
Endokrynol Pol; 2022; 73(4):756-777. PubMed ID: 36059167
[TBL] [Abstract][Full Text] [Related]
3. Current concepts regarding Graves' orbitopathy.
Bartalena L; Tanda ML
J Intern Med; 2022 Nov; 292(5):692-716. PubMed ID: 35604323
[TBL] [Abstract][Full Text] [Related]
4. The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy.
Bartalena L; Baldeschi L; Boboridis K; Eckstein A; Kahaly GJ; Marcocci C; Perros P; Salvi M; Wiersinga WM;
Eur Thyroid J; 2016 Mar; 5(1):9-26. PubMed ID: 27099835
[TBL] [Abstract][Full Text] [Related]
5. Treatment of mild, moderate-to-severe and very severe Graves' orbitopathy.
Marcocci C; Marinò M
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):325-37. PubMed ID: 22632369
[TBL] [Abstract][Full Text] [Related]
6. Treatment options for Graves' orbitopathy.
Marcocci C; Altea MA; Leo M
Expert Opin Pharmacother; 2012 Apr; 13(6):795-806. PubMed ID: 22404364
[TBL] [Abstract][Full Text] [Related]
7. Sight-threatening Graves' orbitopathy: Twenty years' experience of a multidisciplinary thyroid-eye outpatient clinic.
Tramunt B; Imbert P; Grunenwald S; Boutault F; Caron P
Clin Endocrinol (Oxf); 2019 Jan; 90(1):208-213. PubMed ID: 30339291
[TBL] [Abstract][Full Text] [Related]
8. [Thyroid ophthalmopathy at the time of European Group On Graves Orbitopathy (EUGOGO)].
Sadoul JL
Presse Med; 2011 Dec; 40(12 Pt 1):1163-73. PubMed ID: 22119334
[TBL] [Abstract][Full Text] [Related]
9. [Management of Graves' orbitopathy: evidence-based recommendations].
Ponto KA; Pitz S; Mann WJ; Weber MM; Pfeiffer N; Kahaly GJ
Dtsch Med Wochenschr; 2009 Dec; 134(49):2521-4. PubMed ID: 19941237
[TBL] [Abstract][Full Text] [Related]
10. The dilemma of how to manage Graves' hyperthyroidism in patients with associated orbitopathy.
Bartalena L
J Clin Endocrinol Metab; 2011 Mar; 96(3):592-9. PubMed ID: 21190983
[TBL] [Abstract][Full Text] [Related]
11. [Management of patient with Gaves' orbitopathy].
Di Fiore A; Paone L; Rendina R; D'Armiento E; Coccaro C; Alessandrini S; Marenco M; Ulisse S
Clin Ter; 2012 Nov; 163(6):e463-74. PubMed ID: 23306763
[TBL] [Abstract][Full Text] [Related]
12. Optimal management of Graves orbitopathy: a multidisciplinary approach.
Soeters MR; van Zeijl CJ; Boelen A; Kloos R; Saeed P; Vriesendorp TM; Mourits MP
Neth J Med; 2011; 69(7):302-8. PubMed ID: 21934174
[TBL] [Abstract][Full Text] [Related]
13. Graves' orbitopathy: Diagnosis and treatment.
Drui D; Du Pasquier Fediaevski L; Vignal Clermont C; Daumerie C
Ann Endocrinol (Paris); 2018 Dec; 79(6):656-664. PubMed ID: 30177259
[No Abstract] [Full Text] [Related]
14. Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves' ophthalmopathy - a 1-year follow-up: study protocol for a randomized controlled trial.
Brammen L; Riss P; Lukas J; Gessl A; Dunkler D; Li S; Leisser A; Rezar-Dreindl S; Eibenberger K; Selberherr A; Scheuba C; Papp A
Trials; 2018 Sep; 19(1):495. PubMed ID: 30219088
[TBL] [Abstract][Full Text] [Related]
15. Current and Emerging Treatment Strategies for Graves' Orbitopathy.
Genere N; Stan MN
Drugs; 2019 Feb; 79(2):109-124. PubMed ID: 30659423
[TBL] [Abstract][Full Text] [Related]
16. [Graves' ophthalmopathy].
Eckstein A; Dekowski D; Führer-Sakel D; Berchner-Pfannschmidt U; Esser J
Ophthalmologe; 2016 Apr; 113(4):349-64; quiz 465-6. PubMed ID: 27059986
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center.
Tanda ML; Piantanida E; Liparulo L; Veronesi G; Lai A; Sassi L; Pariani N; Gallo D; Azzolini C; Ferrario M; Bartalena L
J Clin Endocrinol Metab; 2013 Apr; 98(4):1443-9. PubMed ID: 23408569
[TBL] [Abstract][Full Text] [Related]
18. [Graves' orbitopathy].
Eckstein A; Möller L; Führer D; Oeverhaus M
Dtsch Med Wochenschr; 2021 Oct; 146(20):1344-1351. PubMed ID: 34644795
[TBL] [Abstract][Full Text] [Related]
19. Antithyroid drugs in Graves' hyperthyroidism: differences between "block and replace" and "titration" regimes in frequency of euthyroidism and Graves' orbitopathy during treatment.
Žarković M; Wiersinga W; Perros P; Bartalena L; Donati S; Okosieme O; Morris D; Fichter N; Lareida J; Daumerie C; Burlacu MC; Kahaly GJ; Pitz S; Beleslin B; Ćirić J; Ayvaz G; Konuk O; Törüner FB; Salvi M; Covelli D; Curro N; Hegedüs L; Brix T;
J Endocrinol Invest; 2021 Feb; 44(2):371-378. PubMed ID: 32524368
[TBL] [Abstract][Full Text] [Related]
20. [Endocrine orbitopathy: the present view of a clinical endocrinologist].
Jiskra J
Vnitr Lek; 2017; 63(10):690-696. PubMed ID: 29127744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
